Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol
about
Bench-to-bedside review: beta2-Agonists and the acute respiratory distress syndromeAirways disease: phenotyping heterogeneity using measures of airway inflammation.Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivoImpaired host defense to Klebsiella pneumoniae infection in mice treated with the PDE4 inhibitor rolipramRoflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide.Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.Inhibition of phosphodiesterase 4 modulates cytokine induction from toll like receptor activated, but not rhinovirus infected, primary human airway smooth muscle.Aspirin attenuates the anti-inflammatory effects of theophylline via inhibition of cAMP production in mice with non-eosinophilic asthmabeta-adrenergic agonists exert their "anti-inflammatory" effects in monocytic cells through the IkappaB/NF-kappaB pathway.Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity.Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD.Differential inhibition of equine neutrophil function by phosphodiesterase inhibitors.The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo.Single-dose pharmacokinetics of roflumilast in children and adolescents.Prevention by theophylline of beta-2-receptor down regulation in healthy subjects.
P2860
Q24806211-04AE04F8-69B0-414E-9DE4-81FFD567CB6EQ33864952-1DE55690-EFC8-4ED8-8C42-2D12C12E0277Q34091087-E682BDEC-ACD7-48C7-A205-9AD61A9A81BEQ34997388-D6AD295D-BE2C-4249-A834-2C268FE47A2AQ35028739-ED544564-D946-46D5-947A-AAB80885B4DAQ35045854-7DFD9A3F-5E27-4638-BDBA-A1A4636307C3Q36025380-63B54B3B-F9E0-4B74-B59C-3573245244C0Q36334968-D20E99EA-5A38-410D-81E7-C422C4103D40Q37320983-84A7B46B-9FF9-418A-8A49-1CDBA5EDCE5BQ38491329-C1F8BF9E-88E4-4C31-A32E-CD23AF6096D3Q40853258-B9D063D9-6F5B-4591-9368-1D544E500EB6Q42857100-E80C3799-CA9A-4C6F-B83D-ED0002327654Q43061572-AFCF8CCD-22F5-4F7A-BD23-FF43F6A969A2Q43736166-984C2CD5-2186-4419-B169-8E6A3ECD60D0Q43897053-6C0439E6-402D-450F-9890-30DE0FF56863Q46570622-52EE1ACB-54A4-4FC9-8425-E78901CF702FQ52415248-B90FDA08-2119-4515-99E1-F31C8A2AB314
P2860
Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol
description
1998 nî lūn-bûn
@nan
1998 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մարտին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Effect of PDE4 inhibitors on z ...... ith prostanoids and salbutamol
@ast
Effect of PDE4 inhibitors on z ...... ith prostanoids and salbutamol
@en
type
label
Effect of PDE4 inhibitors on z ...... ith prostanoids and salbutamol
@ast
Effect of PDE4 inhibitors on z ...... ith prostanoids and salbutamol
@en
prefLabel
Effect of PDE4 inhibitors on z ...... ith prostanoids and salbutamol
@ast
Effect of PDE4 inhibitors on z ...... ith prostanoids and salbutamol
@en
P2093
P2860
P356
P1476
Effect of PDE4 inhibitors on z ...... ith prostanoids and salbutamol
@en
P2093
M M Teixeira
P D Collins
T J Williams
P2860
P304
P356
10.1038/SJ.BJP.0701723
P407
P577
1998-03-01T00:00:00Z